Investors-Gan & Lee

中文站

Careers | Investors | Patients and HCPS | Contact us

Careers Investors Patients and HCPS Contact us

Search

# Popular search #

Diabetes Oncology Medical Devices

Investors

Investors Financial Reports IR Appointment

FY2025 Financial Performance Overview

Operating Income (CNY)

4.052Billion
Increase by 33.1% YOY
Net Profit Attributable Parent (CNY)

1.144 Billion
Increase by 86.1% YOY
Sales Income in China (CNY)

3.506Billion
Increase by 39.6% YOY
International Sales Income (CNY)

529Million
Increase by 36.6% YOY
R&D Input Ratio (R&D Input/Operating Income)

33.1%
R&D Investment 1.341 Billion CNY
Equity Incentive(Around 87 Employees Granted)

7.04 Million
Shares of Restricted Stock Total Shares before the Grant of the Company 1.1849%
Profit Distribution Proposal of the Company 2025（CNY incl.tax）

597 Million Cash Dividend

Our websites

Gangan Technology

You are now leaving the Gan & Lee website.

The site you are about to visit is maintained by a third party who is responsible for its content.
This link is provided on the Gan & Lee website as a service to our visitors. Gan & Lee is not responsible for the privacy policy of any third-party websites. Gan & Lee encourages visitors to read the privacy policy of every website that you may visit.

Continue Back

Search

Operating Income (CNY)

Net Profit Attributable Parent (CNY)

Sales Income in China (CNY)

International Sales Income (CNY)

R&D Input Ratio (R&D Input/Operating Income)

Equity Incentive(Around 87 Employees Granted)

Profit Distribution Proposal of the Company 2025（CNY incl.tax）

Subscribe